气喘治疗市场－全球产业规模、份额、趋势、机会和预测，按药物类别、产品（吸入器、雾化器）、给药途径、地区和竞争格局划分，2020-2030年预测

全球气喘治疗市场规模预计将从2024年的275.2亿美元成长至2030年的343亿美元，年复合成长率（CAGR）为3.74%。气喘治疗涵盖一系列旨在控制和缓解气喘症状的药物和治疗方法。气喘是一种慢性呼吸系统疾病，其特征是气道发炎和狭窄。市场成长的主要驱动因素是全球气喘盛行率的不断上升，尤其是在城市化地区，以及人们对疾病管理意识的提高。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球气喘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（抗发炎药、合併用药、支气管扩张剂）
  • 依产品分类（吸入器、雾化器）
  • 依给药途径（口服、吸入、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲气喘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球气喘治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Teva Pharmaceutical Industries Ltd.
• GSK plc.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca plc.
• Boehringer Ingelheim International GmbH
• Sanofi SA
• Koninklijke Philips NV
• Becton, Dickinson and Company
• Sunovion Pharmaceuticals, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Asthma Therapeutics Market will grow from USD 27.52 Billion in 2024 to USD 34.3 Billion by 2030 at a 3.74% CAGR. Asthma therapeutics encompass a range of pharmaceutical medications and treatment modalities designed to manage and alleviate the symptoms of asthma, a chronic respiratory condition characterized by airway inflammation and narrowing. The market's growth is primarily driven by the escalating global prevalence of asthma, particularly in urbanized regions, and the increasing awareness regarding disease management.

Key Market Drivers

The increasing global asthma prevalence significantly propels the demand for therapeutics. A growing number of individuals worldwide are diagnosed with this chronic respiratory condition, necessitating long-term management and various treatment interventions. This expanding patient population inherently broadens the market for existing medications and drives the need for new therapeutic developments. Factors such as urbanization, increased exposure to environmental allergens, and lifestyle changes contribute to the rising incidence of asthma across diverse demographics.

Key Market Challenges

The high cost associated with advanced biologic therapies represents a significant challenging factor for the global asthma therapeutics market. This elevated pricing directly impacts patient access, particularly in diverse healthcare systems where reimbursement policies or individual financial capacities may be restrictive. Consequently, a substantial portion of the patient population requiring these advanced treatments may face barriers to obtaining them, thereby limiting the overall market penetration and expansion of these innovative therapies.

Key Market Trends

This trend transforms asthma management via real-time data and enhanced medication adherence. Digital health platforms and smart inhalers, with sensors, monitor usage and technique, directly improving treatment efficacy. Over 35 million people in the U.S. lived with a chronic lung condition in 2023, as reported by the American Lung Association in September 2024, highlighting the need for these solutions. Such integration enables personalized adjustments and better patient-provider communication. For example, Adherium announced in April 2024 that its Hailie Smartinhaler received FDA clearance for AstraZeneca's Airsupra and Breztri inhalers, providing real-time medication usage insights. These advancements drive demand for technologically integrated therapeutics.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• GSK plc.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca plc.
• Boehringer Ingelheim International GmbH
• Sanofi S.A.
• Koninklijke Philips N.V.
• Becton, Dickinson and Company
• Sunovion Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Asthma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Therapeutics Market, By Drug Class:

• Anti-inflammatory
• Combination Therapy
• Bronchodilators

Asthma Therapeutics Market, By Product:

• Inhalers
• Nebulizers

Asthma Therapeutics Market, By Route of Administration:

• Oral
• Inhaled
• Others

Asthma Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Asthma Therapeutics Market.

Available Customizations:

Global Asthma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Asthma Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators)
  • 5.2.2. By Product (Inhalers, Nebulizers)
  • 5.2.3. By Route of Administration (Oral, Inhaled, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Asthma Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Product
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Asthma Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. Canada Asthma Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Mexico Asthma Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Route of Administration

7. Europe Asthma Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Product
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Asthma Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. France Asthma Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. United Kingdom Asthma Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. Italy Asthma Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. Spain Asthma Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Route of Administration

8. Asia Pacific Asthma Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Product
  • 8.2.3. By Route of Administration
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Asthma Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. India Asthma Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. Japan Asthma Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Route of Administration
  • 8.3.4. South Korea Asthma Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Route of Administration
  • 8.3.5. Australia Asthma Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Asthma Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Product
  • 9.2.3. By Route of Administration
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Asthma Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. UAE Asthma Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. South Africa Asthma Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Route of Administration

10. South America Asthma Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Product
  • 10.2.3. By Route of Administration
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Asthma Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Colombia Asthma Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. Argentina Asthma Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Asthma Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GSK plc.
• 15.3. Merck & Co., Inc.
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. AstraZeneca plc.
• 15.6. Boehringer Ingelheim International GmbH
• 15.7. Sanofi S.A.
• 15.8. Koninklijke Philips N.V.
• 15.9. Becton, Dickinson and Company
• 15.10. Sunovion Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer